Por: RTTNews Health January 02, 2024
Coherus BioSciences, Inc. () announced that LOQTORZI is now available through select specialty distributors in the United States. LOQTORZI is indicated in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after... + full article
MarketWatch USA Business September 25, 2023
The commercial-stage biopharmaceutical company said the lack of approval came as a result of an ongoing review of inspection findings at a third-party filler. The complete response letter didn't identify any issues with the Udenyca Onbody clinical efficacy or safety, the... + más
Coherus BioSciences: FDA Issues CRL For UDENYCA ONBODY Biologics License Application | RTTNews
'Frustration' fuels Broncos' sideline blowup in loss | ESPN
RTTNews USA Health September 25, 2023
Coherus BioSciences, Inc. () said the FDA issued a Complete Response Letter regarding the Biologics License Application supplement for UDENYCA ONBODY, the company's on-body injector presentation of UDENYCA, solely due to an ongoing review of inspection findings at a... + más
Coherus BioSciences Shares Drop 9% on FDA's Application Rejection | MarketWatch
High school scores and top performers from Friday, March 24 | Orlando Sentinel
WPLG Local 10 USA Health June 30, 2023
Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July. But lower pharmacy bills may not happen right away — or at all — for some patients. That'll... + más
Cheaper competition for Humira is hitting the market, but savings will depend on your insurance | ABC News
How a Drug Company Made $114 Billion by Gaming the U.S. Patent System | The New York Times
ABC News USA Health June 30, 2023
Cheaper competition for Humira is hitting the market, but savings will depend on your insurance | WPLG Local 10
Fox Business USA Business April 16, 2023
Check out what's clicking on FoxBusiness.com Merck & Co. is reportedly in talks to acquire Prometheus Biosciences Inc. The talks are said to be in the late stage with a deal possibly announced as soon as Sunday, according to The Wall Street Journal.A deal is not certain and... + más
Merck to acquire Prometheus Biosciences for $10.8B | Fox Business
Merck Tops Quarterly Profit Estimates but Sees Weaker 2023 Revenue on Lagevrio Sales Drop | MarketWatch
Check out what's clicking on FoxBusiness.com Merck & Co. is acquiring Prometheus Biosciences in a $10.8 billion deal. All the shares of Prometheus Biosciences will be acquired by a subsidiary of Merck for $200 per share.. promising immune disease treatments. The acquisition... + más
Merck in talks to acquire Prometheus Biosciences: report | Fox Business
CNBC USA Tech November 03, 2022
Shara Ticku and David Heller, co-founders of C16 Biosciences.Photo courtesy C16 Biosciences.In July 2013, traveled to Singapore on a work trip for Goldman Sachs. The investment bank made her bring N95 masks to protect her from the terrible air quality at the time.I land in... + más
Ancient Microbes Could Still Be Living on Mars | Time
Nick Gates snaps to Daniel Jones at Wednesday’s practice: ‘I’m happy for him’ | New York Daily News
About iurex | Privacy Policy | Disclaimer |